Loading
Every dated change on the records linked to Small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance. (NCCN 1 (durvalumab consolidation, category 1), ESMO-MCBS A)
Low-dose CT screening in heavy smokers finds some SCLC but stage shift is limited; diagnosis by bronchoscopic or CT-guided biopsy; staging with PET/CT and brain MRI. (NCCN SCLC guideline, staging workup)
Objective response 64 percent after platinum chemotherapy and 85 percent in previously untreated RET fusion-positive non-small-cell lung cancer; intracranial response 91 percent.
At the final analysis (median follow-up 38.
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
Second-line daraxonrasib 300 mg in 26 patients with RAS G12-mutated pancreatic cancer: objective response 35 percent, median progression-free survival 8.
A milestone in how this cancer is treated.
Adjuvant treatment of resected non-small-cell lung cancer after platinum chemotherapy, where PD-L1 is on 50 percent or more of tumour cells and the tumour is not EGFR-mutant or ALK-positive
Untreated extensive-stage small-cell lung cancer, with etoposide and either carboplatin or cisplatin
Resectable non-small-cell lung cancer (4 cm or more, or node positive) without an EGFR mutation or ALK rearrangement, neoadjuvant with platinum chemotherapy then adjuvant alone
Limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy
First-line maintenance with atezolizumab in ES-SCLC (full approval)
Adjuvant treatment of stage IB to IIIA EGFR exon 19 deletion or L858R non-small-cell lung cancer after complete resection
Untreated advanced EGFR mutation-positive non-small-cell lung cancer, with pemetrexed and platinum-based chemotherapy
First-line ES-SCLC with carboplatin-etoposide
Extensive-stage small-cell lung cancer progressing after two or more lines of treatment including platinum-based chemotherapy: not recommended
OS HR 0.
OS 13.
A milestone in how this cancer is treated.
Extensive-stage small-cell lung cancer, first line, with anlotinib and platinum-etoposide chemotherapy
Extensive-stage SCLC after platinum chemotherapy
OS 55.
A milestone in how this cancer is treated.
Objective response 40 percent at the 10 mg dose and 32 percent at 100 mg in previously treated small-cell lung cancer; median progression-free survival 4.
Perioperative durvalumab with neoadjuvant platinum chemotherapy improved event-free survival (hazard ratio 0.
Locally advanced unresectable non-small-cell lung cancer with PD-L1 on 1 percent or more of cells that has not progressed after concurrent platinum-based chemoradiation
First-line ES-SCLC with chemotherapy
OS 15.
OS 15.
Durvalumab with chemotherapy improved progression-free survival (5.
Untreated metastatic non-small-cell lung cancer with PD-L1 on at least 50 percent of tumour cells or 10 percent of tumour-infiltrating immune cells and no EGFR or ALK alteration
To decrease chemotherapy-induced myelosuppression in adults receiving platinum-etoposide or topotecan for extensive-stage small cell lung cancer
OS HR 0.
IMpower010: adjuvant atezolizumab after platinum chemotherapy improved disease-free survival in resected stage II to IIIA non-small-cell lung cancer, most in tumours with PD-L1 on 1 percent or more of tumour cells (hazard ratio 0.
A milestone in how this cancer is treated.
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide
Metastatic SCLC after platinum chemotherapy (accelerated)
Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer
EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer after a first-line EGFR inhibitor
Adjuvant EGFR-mutant NSCLC
Objective response 35.
A milestone in how this cancer is treated.
Metastatic non-squamous non-small-cell lung cancer, with bevacizumab, carboplatin and paclitaxel
Small-cell lung cancer moves faster than non-small-cell lung cancer, in both directions: it grows quickly and it shrinks quickly with treatment. NICE NG122 builds that into the standard. It says (1.8.1) to arrange for people with small-cell lung cancer to have an assessment by a thoracic oncologist within 1 week of deciding to recommend treatment, which is a far shorter interval than anything in the non-small-cell pathway, and (1.10.2) to start radiotherapy during the first or second cycle of chemotherapy for limited-stage disease rather than after the chemotherapy is finished. What that means for you is that the decisions arrive close together and the waiting-for-results pattern that suits advanced non-small-cell disease does not apply here. The treatment divides at limited against extensive stage. Limited stage: 4 to 6 cycles of cisplatin-based combination chemotherapy, with carboplatin substituted where kidney function, performance status or other illnesses make that safer (1.10.1); twice-daily radiotherapy given with the chemotherapy for people with a performance status of 0 or 1 whose disease fits in a radical radiotherapy volume, or once daily if they decline or cannot manage twice (1.10.2 and 1.10.3); sequential radiotherapy for people who are not well enough for concurrent treatment but respond to chemotherapy (1.10.4); preventive radiotherapy to the brain at 25 Gy in 10 fractions for performance status 0 to 2 where the disease has not progressed (1.10.5); and durvalumab afterwards where the disease has not progressed after chemoradiotherapy (1.10.6). Extensive stage: platinum-based combination chemotherapy if you are fit enough, to a maximum of 6 cycles depending on response and toxicity (1.11.1 and 1.11.2), with durvalumab or atezolizumab added (1.11.3), and thoracic radiotherapy with preventive brain radiotherapy considered for people who responded (1.11.4 and 1.11.5). NICE is unusually frank about the cost of preventive brain radiotherapy, saying it can adversely affect quality of life and that the survival benefits are limited, and has an open research question about replacing it with regular MRI scans. At relapse it says to offer assessment by a thoracic oncologist (1.12.1), to tell people whose disease did not respond to first-line treatment that there is very limited evidence that second-line chemotherapy will benefit them (1.12.2), to offer an anthracycline-containing or a further platinum-based regimen to a maximum of 6 cycles where chemotherapy is suitable (1.12.3), and to offer radiotherapy for palliation of local symptoms (1.12.5). Because the decisions arrive close together, three things are worth doing in the first weeks rather than later: the palliative care referral alongside treatment, for symptom control and not instead of it; the conversation with your team about what matters to you; and the practical paperwork Roy Castle's getting organised material covers.
OS 13.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303)
Locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Unresectable stage III NSCLC after chemoradiation
First-line EGFR-mutant NSCLC
OS 12.
A milestone in how this cancer is treated.
Median total hospital days 10.
No significant difference; twice-daily 45 Gy remains standard.
Median overall survival 11.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Relapsed SCLC (oral)
Symptomatic brain metastases at 1 year 14.
Relative risk of death 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.